# Efficacy of a Synthetic Vaccine Derived From Plasmodium Vivax Circumsporozoite Protein (PvCS) in naïve and Semi-immune Volunteers

> **NCT04739917** · PHASE2 · UNKNOWN · sponsor: **Malaria Vaccine and Drug Development Center** · enrollment: 120 (estimated)

## Conditions studied

- Malaria, Vivax

## Interventions

- **BIOLOGICAL:** Vaccine PvCS N+C+R 150 mcg
- **OTHER:** Placebo SSN Montanide ISA-51 1 mL

## Key facts

- **NCT ID:** NCT04739917
- **Lead sponsor:** Malaria Vaccine and Drug Development Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-01
- **Primary completion:** 2022-06-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2021-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04739917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04739917, "Efficacy of a Synthetic Vaccine Derived From Plasmodium Vivax Circumsporozoite Protein (PvCS) in naïve and Semi-immune Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04739917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*